EASL

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data in Treatment of NAFLD at Upcoming EASL International Liver Congress™ 2023

Retrieved on: 
Thursday, June 15, 2023
University of Oxford, EASL, Obesity, NASH, Clinical trial, Non-alcoholic fatty liver disease, NAFLD, Human body weight, Dietary supplement, Patient

GAITHERSBURG, Md., June 15, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Stephen A. Harrison, Medical Director, Pinnacle Clinical Research and Adjunct Professor of Medicine, Oxford University, will present the results of its 24-week clinical trial of pemvidutide in the treatment of non-alcoholic fatty liver disease (NAFLD) in an oral presentation at the EASL International Liver Congress™ 2023 in Vienna, Austria. Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and non-alcohol steatohepatitis (NASH).

Key Points: 
  • Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and non-alcohol steatohepatitis (NASH).
  • A copy of the presentation will be accessible on the Events section of the Altimmune website.
  • Altimmune will host a reception in Vienna for NASH KOLs and investors on Thursday, June 22 at 6:30 PM CEST.
  • Please click here if you are interested in attending the reception and to receive additional details.

Better Therapeutics Announces Upcoming Poster Presentation at EASL Congress 2023 in Vienna, Austria

Retrieved on: 
Friday, June 16, 2023
Technology, Mental Health, Medical Devices, Neurology, Clinical Trials, Cardiology, Software, Other Health, Health, Fatty liver disease, EASL, Cognitive behavioral therapy, Partnership, NASH, PDT, Better, CBT, Congress, Liver disease, MD, Standard of care, NAFLD, Poster, European Association for the Study of the Liver, Principal, FDA, Therapy, Safety, Dietary supplement, Liver

Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing a clinically validated, software-based, novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases, today announced the details of its poster presentation at the European Association for the Study of the Liver ( EASL ) Congress 2023, being held from June 21-24 in Vienna, Austria.

Key Points: 
  • Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing a clinically validated, software-based, novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases, today announced the details of its poster presentation at the European Association for the Study of the Liver ( EASL ) Congress 2023, being held from June 21-24 in Vienna, Austria.
  • The study was designed in partnership with Better Therapeutics to explore the safety, efficacy, and usability of a novel PDT platform, in individuals with NAFLD or NASH.
  • Following the successful completion of the LivVita Liver Study, Better Therapeutics commenced work on an application to the FDA for Breakthrough Device Designation.
  • Topline results from the LivVita Study from Better Therapeutics’ public announcement can be viewed here .

SUMMIT CLINICAL RESEARCH IN COLLABORATION WITH NAIL-NIT CONSORTIUM TO PRESENT GROUNDBREAKING DATA AT THE EASL CONFERENCE FROM OVER 5,000 PATIENTS COMBINED FROM MULTIPLE CLINICAL TRIALS

Retrieved on: 
Thursday, June 15, 2023
Abstract, EASL, NASH, Liver, Diabetes, Houston Methodist Hospital, Congress, Date, Committee, AGA, Data, Patient, SAN, Fatty liver disease, Non-alcoholic fatty liver disease, European Association for the Study of the Liver, Cirrhosis, Disease, Medical device, Medicine

OS—026: Performance of the AGA clinical care pathway in identifying patients with at-risk non-alcoholic steatohepatitis: combined data from multiple therapeutic clinical trials including more than 5,000 patients (in collaboration with NAIL-NIT Consortium).

Key Points: 
  • OS—026: Performance of the AGA clinical care pathway in identifying patients with at-risk non-alcoholic steatohepatitis: combined data from multiple therapeutic clinical trials including more than 5,000 patients (in collaboration with NAIL-NIT Consortium).
  • Date 22 June, presenter Dr. Naim Alkhouri
    THU-413: Deep dive analysis into the screening failure reasons: combined data from multiple therapeutic clinical trials including more than 5,000 patients (in collaboration with NAIL-NIT Consortium).
  • THU-439: Glycated hemoglobin as an independent predictor of hepatocyte ballooning in non-alcoholic steatohepatitis: combined data from multiple clinical trials including more than 5,000 patients (in collaboration with NAIL-NIT Consortium).
  • Date 22 June, presenter Dr. Mazen Noureddin
    THU-552: Comparison of non-alcoholic steatohepatitis severity between Hispanics and non-Hispanics: combined data from multiple therapeutic clinical trials including more than 5,000 patients (in collaboration with NAIL-NIT Consortium).

HistoIndex SHG/TPE imaging and AI-based technology reveals dose-dependent effectiveness of Tropifexor for NASH patients in Nature Medicine

Retrieved on: 
Thursday, June 15, 2023
Photon, EASL, TPE, CET, NASH, Hepatology, Liver disease, Non-alcoholic fatty liver disease, Second-harmonic imaging microscopy, Clinical trial, Medicine, Congress, Fibrosis, VCU, Patient, Artificial intelligence, Liver, Diagnosis, AI, SHG, Cirrhosis, Medical imaging, Nature Medicine

This is mainly because traditional liver histopathology assessment of fibrosis is qualitative, nonlinear between stages, and requires substantial changes over a relatively short time before a response can be detected.

Key Points: 
  • This is mainly because traditional liver histopathology assessment of fibrosis is qualitative, nonlinear between stages, and requires substantial changes over a relatively short time before a response can be detected.
  • These biopsies were also assessed by conventional microscopy and traditional histologic scoring systems based on the categorical fibrosis stage.
  • While the conventional methods showed that only a proportion of patients achieved fibrosis improvement, the AI-based qFibrosis® algorithm showed a dose-dependent increase in the proportion of patients who achieved fibrosis improvement.
  • Tropifexor treatment was also associated with a dose-dependent reduction in qSteatosis®, which was also confirmed by a statistically significant correlation with the quantitative MRI-based evaluation of fat reduction.

TANDEM study shows potential of HistoIndex SHG/TPE imaging and AI-based technology in evaluating the effects of combination therapy for NASH

Retrieved on: 
Thursday, June 15, 2023
Photon, Steatosis, EASL, FXR, CET, NASH, Second-harmonic imaging microscopy, Research, Inflammation, Tropifexor, Congress, Fibrosis, HIV disease progression rates, Patient, Artificial intelligence, CCR5, TANDEM, Fatty liver disease, Digital, AI, Newcastle University, CCR2, SHG, Cenicriviroc, Medical imaging

The study, published recently in Hepatology , compared the effectiveness of Tropifexor plus Cenicriviroc combination therapy versus monotherapy1.

Key Points: 
  • The study, published recently in Hepatology , compared the effectiveness of Tropifexor plus Cenicriviroc combination therapy versus monotherapy1.
  • The study found that the AI-based analysis using SHG/TPE digital pathology was able to detect effects seen in different zones of the liver lobule that may not have been detected using conventional microscopy.
  • The fully quantitative co-localization and zonal assessment has the potential to provide greater details in evaluating the effects of combination therapy for NASH.
  • Tropifexor is a selective agonist of farnesoid X receptor (FXR), which regulates bile acid metabolism and inflammation.

Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the European Association for the Study of the Liver (EASL) Congress 2023

Retrieved on: 
Thursday, June 15, 2023
University College London, PFS, EASL, ACLF, Use, Royal Free Hospital, HRS, SCR, International Club Crosby, Research, Transplant, MNK, Doctor of Philosophy, EDT, Bachelor of Science, Congress, California Pacific Medical Center, Volume overload, Hepatorenal syndrome, Oxygen saturation (medicine), MD, Patient, Risk, CEST, Boxed warning, Kidney, Diagnosis, Terlipressin, Hypoxia, European Association for the Study of the Liver, ICA, Digestate, UCL Institute of Ophthalmology, NYSE, Respiratory failure, Dietary supplement, Pharmaceutical industry, Nursing, Mallinckrodt, Liver

DUBLIN, June 15, 2023 /PRNewswire/ -- Mallinckrodt plc (NYSE American: MNK), a global specialty pharmaceutical company, today announced that two scientific posters detailing Mallinckrodt's latest research findings on the clinical outcomes of treatment with TERLIVAZ® (terlipressin) for injection and clinical management criteria for adult patients with hepatorenal syndrome (HRS) will be presented at the European Association for the Study of the Liver (EASL) Congress 2023 in Vienna, Austria, taking place June 21-24, 2023. Both posters will be presented on June 24, 2023, 9:00 a.m. – 5:00 p.m. CEST / 3:00 a.m. – 11:00 a.m. EDT.

Key Points: 
  • Both posters will be presented on June 24, 2023, 9:00 a.m. – 5:00 p.m. CEST / 3:00 a.m. – 11:00 a.m. EDT.
  • The CONFIRM trial is the largest-ever prospective, randomized clinical trial of terlipressin compared to placebo in patients with HRS type 1 (HRS-1).
  • Ineligibility for Liver Transplant: TERLIVAZ-related adverse reactions (respiratory failure, ischemia) may make a patient ineligible for liver transplantation, if listed.
  • For patients with high prioritization for liver transplantation (e.g., MELD ≥35), the benefits of TERLIVAZ may not outweigh its risks.

Merck to Present Data for Efinopegdutide (MK-6024), an Investigational GLP-1/Glucagon Receptor Co-agonist, in Patients with Nonalcoholic Fatty Liver Disease (NAFLD) at EASL 2023

Retrieved on: 
Monday, June 12, 2023
Biotechnology, FDA, Diabetes, Health, General Health, Pharmaceutical, Oncology, Research, Science, Veterinary, Clinical Trials, MSD, EASL, NASH, MRK, Inflammation, Merck & Co., Congress, Patient, CEST, Fatty liver disease, NAFLD, European Association for the Study of the Liver, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Fast track (FDA), NYSE, Food, Safety, Pharmaceutical industry, Liver, Merck

Data to be shared include results from the Phase 2a clinical trial evaluating efinopegdutide in adult patients with nonalcoholic fatty liver disease (NAFLD).

Key Points: 
  • Data to be shared include results from the Phase 2a clinical trial evaluating efinopegdutide in adult patients with nonalcoholic fatty liver disease (NAFLD).
  • Separately, efinopegdutide was recently granted Fast Track Designation from the U.S. Food and Drug Administration (FDA) as a potential treatment for patients with nonalcoholic steatohepatitis (NASH), a more severe form of NAFLD that includes inflammation and damage to the liver.
  • Fast Track is a process designed to facilitate the development and expedite the review of drug candidates to treat serious conditions and fulfill an unmet medical need.
  • “We are looking forward to sharing detailed findings from the Phase 2a study of efinopegdutide with the scientific community at the EASL Congress,” said Sam Engel, associate vice president, global clinical development, Merck Research Laboratories.

Intercept Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC to be Featured in Podium Presentation at EASL Congress 2023

Retrieved on: 
Wednesday, June 7, 2023
Intercept, EASL, Research and development, Bezafibrate, Therapy, Serum, PBC, Alanine transaminase, Obeticholic acid, Safety, GGT, Aes, ALP, Biomarker, Alkaline phosphatase, Congress, Development, Primary biliary cholangitis, Patient, Data, Intercept Pharmaceuticals, Itch, OCA, Randomness, UDCA, Effect, ALT, European Association for the Study of the Liver, FDA, AST, Interim analysis, Pharmaceutical industry, Medical imaging, Liver

MORRISTOWN, N.J., June 07, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced initial results from a planned interim analysis of its ongoing Phase 2 study 747-213, an active comparator trial demonstrating the therapeutic potential of the combination of obeticholic acid (OCA) and bezafibrate vs. bezafibrate monotherapy on serum biomarkers in primary biliary cholangitis (PBC). These data are part of a larger analysis that will be presented at 08:45 CEST on Friday, June 23 at the European Association for the Study of the Liver (EASL) Congress 2023 in Vienna, Austria.

Key Points: 
  • Safety was assessed by monitoring of adverse events (AEs) and laboratory values.
  • “Multiple real-world studies have demonstrated improved transplant-free survival of OCALIVA (obeticholic acid) following improvements in a specific combination of biomarkers.
  • We are encouraged by the best-in-class potential of our novel combination to build on this evidence with rapid biochemical responses that have predicted improved clinical outcomes.
  • “Results from a Planned Interim Analysis of a Randomized, Double-Blind, Active-Controlled Trial Evaluating the Effects of Obeticholic Acid and Bezafibrate on Serum Biomarkers in Primary Biliary Cholangitis” Abstract #2495

89bio Announces Late-Breaker Oral Presentation of Data from the Phase 2 ENLIVEN Study of Pegozafermin at EASL International Liver Congress 2023

Retrieved on: 
Wednesday, June 7, 2023
EASL, University, NASH, University of California, San Diego, Congress, Patient, SAN, Fatty liver disease, NAFLD, European Association for the Study of the Liver, Pharmaceutical industry, Liver

SAN FRANCISCO, June 07, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that pegozafermin data in nonalcoholic steatohepatitis (NASH) will be featured in a late-breaker oral presentation during the European Association for the Study of the Liver (EASL) Congress 2023 to be held June 21-24, 2023 in Vienna, Austria.

Key Points: 
  • SAN FRANCISCO, June 07, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that pegozafermin data in nonalcoholic steatohepatitis (NASH) will be featured in a late-breaker oral presentation during the European Association for the Study of the Liver (EASL) Congress 2023 to be held June 21-24, 2023 in Vienna, Austria.
  • The presentation was selected for inclusion in the Best of EASL Congress summary slide deck that highlights the most noteworthy contributions to the scientific program at EASL.
  • Details for the late-breaker oral presentation are as follows:
    Abstract Title: Pegozafermin for the treatment of non-alcoholic steatohepatitis patients with F2/F3 fibrosis: a multi-center, randomized, double-blind, placebo-controlled Phase 2b trial (ENLIVEN)
    Presenting Author: Rohit Loomba, M.D., MHSc, Director, NAFLD Research Center, University of California San Diego, and lead investigator of ENLIVEN
    89bio will also present data from a preclinical study.
  • Presentation details are as follows:

Aligos Therapeutics to Present Data on its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023

Retrieved on: 
Wednesday, June 7, 2023
PK, Asos, Abstract, DNA, Conference, EASL, SSO, Therapy, Doctor of Philosophy, Liver disease, Serum, Safety, Pharmacokinetics, CHB, MBA, Hepatitis B virus, RNA, NAP, AAV, Hepatocyte, Small RNA, Congress, Patient, SAN, Mouse, European Association for the Study of the Liver, ETV, PD-1, HBV, Hepatitis, State Police Services, Pharmaceutical industry, Vaccine, Palladium, Liver, HBsAg

“These presentations highlight the progress we have made advancing new potentially best-in-class compounds,” said Lawrence Blatt, Ph.D., MBA, Chairman & CEO of Aligos Therapeutics.

Key Points: 
  • “These presentations highlight the progress we have made advancing new potentially best-in-class compounds,” said Lawrence Blatt, Ph.D., MBA, Chairman & CEO of Aligos Therapeutics.
  • The presentations will be available on the Scientific Presentations and Conferences page on Aligos’ corporate website following the meeting.
  • Additionally, the pharmacodynamic response of HBsAg reduction and durability correlated with total siRNA and RISC-bound siRNA in mouse liver.
  • There is the potential for a significantly improved therapeutic window by precision targeting of only the DNA transactivating region of the multifunctional β-catenin protein.